PLTRPalantir Technologies

$208.45+18% 1Y
Latest close: a new 52-week highOct 9, 2026what changed →

Is the business good?

Excellent

A genuinely good business: 7 of 9 health tests passed, earnings fully cash-backed (1.3×), and margins widening.

4 good
Fundamental health (F-score)7 / 9SEC EDGAR · Dec 31, 2025

High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.31×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is worsening vs a year ago.

Margin direction, 3 years+45.3 pts

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Where ROE comes from20% ROA

High-quality, exceptional returns on the assets themselves, not leverage. ROE 24% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionmiddle of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is PLTR?

Palantir Technologies keeps 43% of every revenue dollar as operating profit, against 5.8% for the median Software - Infrastructure name.

43%

Operating margin · Software - Infrastructure median 5.8% · 12 months to Q2 2026

Cash conversion
1.31×

Cash conversion · 3.12× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
+0.23%

Share count, year on year · flat: no meaningful dilution

R&D as % of revenue
10%

R&D as % of revenue

Operating margin by fiscal year
YearOperating margin
FY2020−107%
FY2021−27%
FY2022−8.5%
FY20235.4%
FY202411%
FY202532%
Details›
Gross margin12 months to Q2 2026
85%
Operating margin12 months to Q2 2026
43%
Net margin12 months to Q2 2026
49%
Free cash flow margin
55%
R&D as % of revenue
10%
Revenue, trailing twelve months
$6.16B
Free cash flow, trailing twelve months
$3.36B
Net income, trailing twelve months
$3.02B

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.

On our screens:R&D leaders